Taiji Group: DSC158A slice approved for clinical trials

Taiji Group Announcement: Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Taiji Group, has received the "Drug Clinical Trial Approval Notice" for DSC158A tablets issued by the National Medical Products Administration. DSC158A tablets are a new generation RNA polymerase inhibitor independently developed by the company, intended for the treatment of adult influenza A and B. Preclinical studies have shown that DSC158A tablets can effectively improve symptoms in model mice at lower doses, and also demonstrate good tolerability and a large safety window.